JP2009502135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502135A5 JP2009502135A5 JP2008522923A JP2008522923A JP2009502135A5 JP 2009502135 A5 JP2009502135 A5 JP 2009502135A5 JP 2008522923 A JP2008522923 A JP 2008522923A JP 2008522923 A JP2008522923 A JP 2008522923A JP 2009502135 A5 JP2009502135 A5 JP 2009502135A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- complex
- cargo compound
- transport
- cargo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 108010092351 cupredoxin Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108010007337 Azurin Proteins 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- 208000017194 Affective disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000003098 Ganglion Cysts Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 241000588653 Neisseria Species 0.000 claims 1
- 208000008846 Neurocytoma Diseases 0.000 claims 1
- 101150006573 PAN1 gene Proteins 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 108090000051 Plastocyanin Proteins 0.000 claims 1
- 108090000035 Pseudoazurin Proteins 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000005400 Synovial Cyst Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 201000002785 amyotrophic lateral sclerosis type 11 Diseases 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000002961 echo contrast media Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 201000008361 ganglioneuroma Diseases 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000000185 intracerebroventricular administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 210000005171 mammalian brain Anatomy 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 238000000386 microscopy Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 claims 1
- 206010073131 oligoastrocytoma Diseases 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 108010086158 rusticyanin Proteins 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 238000012285 ultrasound imaging Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70029705P | 2005-07-19 | 2005-07-19 | |
| US11/244,105 US7691383B2 (en) | 2004-10-07 | 2005-10-06 | Cupredoxin derived transport agents and methods of use thereof |
| US81851006P | 2006-07-06 | 2006-07-06 | |
| PCT/US2006/028022 WO2007012004A2 (en) | 2005-07-19 | 2006-07-19 | Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009502135A JP2009502135A (ja) | 2009-01-29 |
| JP2009502135A5 true JP2009502135A5 (enExample) | 2009-09-10 |
Family
ID=37669545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522923A Pending JP2009502135A (ja) | 2005-07-19 | 2006-07-19 | 血液脳関門を越えるための、および脳癌細胞内への輸送因子、並びにその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US7807183B2 (enExample) |
| EP (1) | EP1904642A4 (enExample) |
| JP (1) | JP2009502135A (enExample) |
| KR (1) | KR20080042804A (enExample) |
| AU (1) | AU2006269879A1 (enExample) |
| BR (1) | BRPI0615562A2 (enExample) |
| CA (1) | CA2615617A1 (enExample) |
| IL (1) | IL188719A0 (enExample) |
| MX (1) | MX2008000994A (enExample) |
| NO (1) | NO20080830L (enExample) |
| WO (1) | WO2007012004A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7491394B2 (en) | 2001-02-15 | 2009-02-17 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
| US7381701B2 (en) | 2001-02-15 | 2008-06-03 | The Borad Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins |
| JP4903036B2 (ja) * | 2003-01-06 | 2012-03-21 | アンジオケム・インコーポレーテッド | 血液脳関門を通過する担体としてのアプロチニンおよび類似体 |
| US10675326B2 (en) | 2004-10-07 | 2020-06-09 | The Board Of Trustees Of The University Of Illinois | Compositions comprising cupredoxins for treating cancer |
| WO2007009229A1 (en) | 2005-07-15 | 2007-01-25 | Angiochem Inc. | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates |
| JP2009502135A (ja) * | 2005-07-19 | 2009-01-29 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 血液脳関門を越えるための、および脳癌細胞内への輸送因子、並びにその使用方法 |
| KR20090059148A (ko) * | 2006-09-11 | 2009-06-10 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | 쿠프레독신 유래된 펩티드의 변형 및 이의 이용 방법 |
| EP2089411A4 (en) | 2006-12-04 | 2010-01-27 | Univ Illinois | COMPOSITIONS AND METHODS FOR CANCER TREATMENT WITH CUPREDOXINES AND CPG-RICH DNA |
| AU2008212788A1 (en) * | 2007-02-08 | 2008-08-14 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to prevent cancer with cupredoxins |
| US9365634B2 (en) * | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| CA2702494A1 (en) | 2007-10-19 | 2009-04-23 | The Regents Of The University Of California | Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss |
| EP2604704B1 (en) * | 2008-02-01 | 2018-10-03 | The General Hospital Corporation | Use of microvesicles in diagnosis and prognosis of brain tumor |
| WO2009127072A1 (en) | 2008-04-18 | 2009-10-22 | Angiochem Inc. | Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use |
| WO2010043047A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| CA2740317A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
| US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| AU2009327267A1 (en) | 2008-12-17 | 2011-07-14 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| ES2729261T3 (es) | 2009-04-20 | 2019-10-31 | Angiochem Inc | Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2 |
| WO2011000095A1 (en) | 2009-07-02 | 2011-01-06 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| ES2562463T3 (es) * | 2009-07-14 | 2016-03-04 | Mayo Foundation For Medical Education And Research | Administración no covalente, mediada por péptidos, de agentes activos a través de la barrera hematoencefálica |
| EP3461912B1 (en) | 2009-09-09 | 2022-07-13 | The General Hospital Corporation | Use of microvesicles in analyzing nucleic acid profiles |
| EP2475989A4 (en) | 2009-09-09 | 2013-02-27 | Gen Hospital Corp | USE OF MICROVESICLES IN THE ANALYSIS OF KRAS MUTATIONS |
| US20140045915A1 (en) | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| US20130287808A1 (en) * | 2010-11-05 | 2013-10-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vaccines for preventing meningococcal infections |
| EP2638057B1 (en) | 2010-11-10 | 2019-03-06 | Exosome Diagnostics, Inc. | Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom |
| EP2788087A4 (en) * | 2011-12-06 | 2015-08-26 | Ohio State Innovation Foundation | Non-ionic, low-osmolar contrast agents for the administration of antisense oligonucleotides and the treatment of diseases |
| AU2013295242C1 (en) | 2012-07-27 | 2018-08-09 | Institut National De La Sante Et De La Recherche Medicale | CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
| JP2015526434A (ja) | 2012-08-14 | 2015-09-10 | アンジオケム インコーポレーテッド | ペプチド−デンドリマーコンジュゲート及びその使用 |
| KR102166549B1 (ko) * | 2014-01-10 | 2020-10-16 | 주식회사 젬백스앤카엘 | 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트 |
| JP2017506884A (ja) * | 2014-01-17 | 2017-03-16 | ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ | 活性薬の送達を増強するための方法 |
| US10039808B2 (en) | 2014-10-22 | 2018-08-07 | Michael Chez | Method of treating or improving neurological function in a human subject |
| US9925244B1 (en) | 2015-02-17 | 2018-03-27 | Michael Chez | Treatment of warts in non-immunosuppressed patients |
| WO2016176573A1 (en) | 2015-04-30 | 2016-11-03 | Board Of Regents, The University Of Texas System | Antibacterial polypeptide libraries and methods for screening the same |
| EP3307326B9 (en) | 2015-06-15 | 2021-02-24 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
| US10072065B2 (en) | 2015-08-24 | 2018-09-11 | Mayo Foundation For Medical Education And Research | Peptide-mediated delivery of immunoglobulins across the blood-brain barrier |
| US11752315B1 (en) | 2016-10-07 | 2023-09-12 | Carlos A. Hakim | Method of treating normal pressure hydrocephalus |
| US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
| US20220241337A1 (en) * | 2019-02-22 | 2022-08-04 | The Trustees Of Columbia University In The City Of Newyork | Preparing tissues for delivery of therapeutic and diagnostic agents and delivering the agents |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5827934A (en) | 1988-03-08 | 1998-10-27 | The University Of Wyoming | Cytotoxic diphtheria toxin fragments |
| US5972899A (en) | 1996-01-25 | 1999-10-26 | New York University | Apoptosis induced by Shigella IpaB |
| EP1144605B1 (en) | 1999-01-26 | 2009-12-16 | University College London | Dimethylarginine dimethylaminohydrolases |
| US6800437B1 (en) * | 1999-08-06 | 2004-10-05 | Tibotec Bvba | Method of monitoring a biological system by labeling with an apo metal binding protein |
| US20020164703A1 (en) | 2000-12-21 | 2002-11-07 | Krzysztof Pawlowski | Card-domain containing polypeptides, encoding nucleic acids, and methods of use |
| GB0103424D0 (en) * | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| US7338766B2 (en) * | 2001-02-15 | 2008-03-04 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating malaria with cupredoxin and cytochrome |
| US7491394B2 (en) | 2001-02-15 | 2009-02-17 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
| KR100955973B1 (ko) | 2001-02-15 | 2010-05-04 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | 세포 사멸을 조절하는 세포독성인자 |
| US7301010B2 (en) * | 2001-02-15 | 2007-11-27 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating HIV infection with cupredoxin and cytochrome c |
| EP1390499A2 (en) * | 2001-03-02 | 2004-02-25 | Florigene Limited | Cell visual characteristic-modifying sequences |
| GB0211295D0 (en) | 2002-05-16 | 2002-06-26 | Univ London | Treatment of pain |
| US20070059329A1 (en) | 2002-11-15 | 2007-03-15 | Nathalie Norais | Unexpected surface proteins in meningococcus |
| CN101437842A (zh) | 2004-10-07 | 2009-05-20 | 阿南达·查克拉博蒂 | 铜氧还蛋白衍生的转运制剂及其应用方法 |
| US7377597B2 (en) | 2005-02-15 | 2008-05-27 | Geo Plastics | Wheel assembly having wheel-mounting sleeve and retainer |
| CA2608512A1 (en) | 2005-05-20 | 2007-02-15 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins |
| CA2608398A1 (en) | 2005-05-20 | 2006-11-30 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating hiv infection with cupredoxin and cytochrome c |
| JP2009504567A (ja) | 2005-05-20 | 2009-02-05 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | クプレドキシンおよびシトクロムでマラリアを治療するための組成物および方法 |
| JP2009502135A (ja) * | 2005-07-19 | 2009-01-29 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 血液脳関門を越えるための、および脳癌細胞内への輸送因子、並びにその使用方法 |
| KR20090059148A (ko) | 2006-09-11 | 2009-06-10 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | 쿠프레독신 유래된 펩티드의 변형 및 이의 이용 방법 |
| RU2009113812A (ru) | 2006-09-14 | 2010-10-20 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) | Композиции и способы для профилактики рака с помощью купредоксинов |
| AU2008212788A1 (en) | 2007-02-08 | 2008-08-14 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to prevent cancer with cupredoxins |
| WO2009078977A2 (en) | 2007-12-14 | 2009-06-25 | Cdg Therapeutics Inc | Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins |
| GB0802126D0 (en) | 2008-02-05 | 2008-03-12 | Level 5 Networks Inc | Scalable sockets |
-
2006
- 2006-07-19 JP JP2008522923A patent/JP2009502135A/ja active Pending
- 2006-07-19 AU AU2006269879A patent/AU2006269879A1/en not_active Abandoned
- 2006-07-19 US US11/488,695 patent/US7807183B2/en not_active Expired - Fee Related
- 2006-07-19 MX MX2008000994A patent/MX2008000994A/es active IP Right Grant
- 2006-07-19 WO PCT/US2006/028022 patent/WO2007012004A2/en not_active Ceased
- 2006-07-19 KR KR1020087002479A patent/KR20080042804A/ko not_active Ceased
- 2006-07-19 BR BRPI0615562-6A patent/BRPI0615562A2/pt not_active IP Right Cessation
- 2006-07-19 EP EP06787848A patent/EP1904642A4/en not_active Withdrawn
- 2006-07-19 CA CA002615617A patent/CA2615617A1/en not_active Abandoned
-
2008
- 2008-01-10 IL IL188719A patent/IL188719A0/en unknown
- 2008-02-15 NO NO20080830A patent/NO20080830L/no not_active Application Discontinuation
-
2010
- 2010-10-04 US US12/897,298 patent/US8188251B2/en not_active Expired - Lifetime
-
2012
- 2012-05-25 US US13/481,018 patent/US8545812B2/en not_active Expired - Fee Related
-
2013
- 2013-09-30 US US14/041,184 patent/US9309292B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009502135A5 (enExample) | ||
| CN112618956B (zh) | 使用交变电场来提高血脑屏障的通透性 | |
| Saxena et al. | Nanocarrier-mediated inhibition of macrophage migration inhibitory factor attenuates secondary injury after spinal cord injury | |
| EP2282763B1 (en) | Process for preparing supramolecular calcitonin assemblies (SCA) | |
| Dhuria et al. | Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system | |
| Pardridge | Drug delivery to the brain | |
| US9597408B2 (en) | Peptide-mediated non-covalent delivery of active agents across the blood-brain barrier | |
| Ksendzovsky et al. | Convection-enhanced delivery of M13 bacteriophage to the brain | |
| US20200317734A1 (en) | Amyloid-beta-binding peptides and the use thereof for the treatment and diagnosis of alzheimer's disease | |
| Mcgowan et al. | Intranasal administration of elastin-like polypeptide for therapeutic delivery to the central nervous system | |
| WO2018106273A1 (en) | Collagen targeting nanofibers and nanosheets | |
| Ulapane et al. | In vivo brain delivery and brain deposition of proteins with various sizes | |
| Karande et al. | Novel approaches for the delivery of biologics to the central nervous system | |
| Su et al. | Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles | |
| US20240398978A1 (en) | Compositions and Methods for Treating Dopamine Disorders | |
| Ebert et al. | Delivery of neuroregenerative proteins to the brain for treatments of neurodegenerative brain diseases | |
| Park et al. | Controlled drug delivery: present and future | |
| Lawrence | William Pardridge discusses the lack of BBB research | |
| Pardridge et al. | William Pardridge discusses the lack of BBB research | |
| JP2005508875A5 (enExample) | ||
| Pathak et al. | Drug delivery to the brain: targeting technologies to deliver therapeutics to brain lesions | |
| RU2008106230A (ru) | Средства проникновения через гематоэнцефалический барьер и внутрь клеток раковой опухоли мозга и способы их использования | |
| Upadhaya et al. | Diagnostic and theranostic intranasal nanointerventions for brain diseases | |
| Ouyang et al. | Rimota-Gd: Paramagnetic Probe for In Vivo MRI Studies of the Cannabinoid 1 Receptor Distribution in the Mouse Brain | |
| Chu et al. | The future neurotrophic factor therapy in Parkinson's disease |